SARAF

Across TCGA pan-cancer cohorts, SARAF Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SARAF data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SARAF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SARAF expression acts as an unfavorable survival marker.

SKCM are the cancer types where SARAF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.245	0.781	.008	15	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SARAF–SKCM (OS)

Open the SKCM breakdown →